VYNE Therapeutics (VYNE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

VYNE Stock Forecast

VYNE Therapeutics stock forecast is as follows: an average price target of $5.75 (represents a 130.00% upside from VYNE’s last price of $2.50) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

VYNE Price Target

The average price target for VYNE Therapeutics (VYNE) is $5.75 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.75 to $5.75. This represents a potential 130.00% upside from VYNE's last price of $2.50.

VYNE Analyst Ratings

Buy

According to 2 Wall Street analysts, VYNE Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VYNE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

VYNE Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 14, 2024	Joseph Pantginis	H.C. Wainwright	$5.75	$2.11	172.51%	130.00%

The latest VYNE Therapeutics stock forecast, released on Jun 14, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $5.75, which represents a 172.51% increase from the stock price at the time of the forecast ($2.11), and a 130.00% increase from VYNE last price ($2.50).

VYNE Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$5.75
Last Closing Price	$2.50	$2.50	$2.50
Upside/Downside	-100.00%	-100.00%	130.00%

In the current month, the average price target of VYNE Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VYNE Therapeutics's last price of $2.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 13, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 15, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 14, 2024	H.C. Wainwright	Buy	Buy	Hold

VYNE Therapeutics's last stock rating was published by H.C. Wainwright on Sep 13, 2024. The company gave VYNE a "Buy" rating, the same as its previous rate.

VYNE Therapeutics Financial Forecast

VYNE Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Mar 18
Revenue	-	-	-	-	-	-	-	-	$76.00K	$114.00K	$135.00K	$99.00K	$6.00K	$167.00K	$126.00K	$178.00K	$2.29M	$4.09M	$4.26M	$4.12M	$4.29M	$3.27M	$11.69M	$1.75M	-	$497.00K
Avg Forecast	$100.00K	$100.00K	$100.00K	$100.00K	$140.00K	$110.00K	$110.00K	$100.00K	$150.00K	$150.00K	$50.00K	$6.29M	$60.00K	$50.00K	$100.00K	$366.67K	$4.02M	$4.76M	$6.35M	$4.77M	$4.71M	$3.31M	$1.59M	$1.57M	$12.40M	$11.36M
High Forecast	$116.67K	$116.67K	$116.67K	$116.67K	$163.33K	$128.33K	$128.33K	$116.67K	$175.00K	$175.00K	$58.33K	$7.55M	$70.00K	$50.00K	$100.00K	$366.67K	$4.02M	$4.76M	$6.35M	$4.77M	$4.71M	$3.31M	$1.59M	$1.57M	$14.88M	$13.64M
Low Forecast	$83.33K	$83.33K	$83.33K	$83.33K	$116.67K	$91.67K	$91.67K	$83.33K	$125.00K	$125.00K	$41.67K	$5.03M	$50.00K	$50.00K	$100.00K	$366.67K	$4.02M	$4.76M	$6.35M	$4.77M	$4.71M	$3.31M	$1.59M	$1.57M	$9.92M	$9.09M
# Analysts	1	1	1	1	1	1	1	1	1	1	13	14	6	6	8	6	7	11	7	13	10	16	8	11	17	14
Surprise %	-	-	-	-	-	-	-	-	0.51%	0.76%	2.70%	0.02%	0.10%	3.34%	1.26%	0.49%	0.57%	0.86%	0.67%	0.86%	0.91%	0.99%	7.37%	1.12%	-	0.04%

VYNE Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $100.00K, with a low forecast of $83.33K, and a high forecast of $116.67K. VYNE's average Quarter revenue forecast represents a 31.58% increase compared to the company's last Quarter revenue of $76.00K (Dec 23).

VYNE Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	13	14	6	6	8	6	7	11	7	13	10	16	8	11	17	14
EBITDA	-	-	-	-	-	-	-	-	$-5.45M	$-6.23M	$-10.32M	$-5.88M	$-7.75M	$-9.08M	$-8.22M	$-8.65M	$-11.99M	$-17.78M	$-18.82M	$-19.46M	$-22.27M	$-23.42M	$-166.52M	$-39.07M	$-18.68M	$-12.65M
Avg Forecast	$-100.00K	$-100.00K	$-100.00K	$-100.00K	$-140.00K	$-110.00K	$-110.00K	$-37.60M	$-150.00K	$-150.00K	$-50.00K	$-29.72M	$-17.10M	$-50.00K	$-100.00K	$-23.50M	$-4.02M	$-4.76M	$-6.35M	$-21.36M	$-4.71M	$-3.31M	$-1.59M	$-34.42M	$-19.48M	$-11.50M
High Forecast	$-83.33K	$-83.33K	$-83.33K	$-83.33K	$-116.67K	$-91.67K	$-91.67K	$-30.08M	$-125.00K	$-125.00K	$-41.67K	$-23.78M	$-13.68M	$-50.00K	$-100.00K	$-18.80M	$-4.02M	$-4.76M	$-6.35M	$-17.09M	$-4.71M	$-3.31M	$-1.59M	$-27.54M	$-15.58M	$-9.20M
Low Forecast	$-116.67K	$-116.67K	$-116.67K	$-116.67K	$-163.33K	$-128.33K	$-128.33K	$-45.12M	$-175.00K	$-175.00K	$-58.33K	$-35.67M	$-20.53M	$-50.00K	$-100.00K	$-28.19M	$-4.02M	$-4.76M	$-6.35M	$-25.63M	$-4.71M	$-3.31M	$-1.59M	$-41.31M	$-23.37M	$-13.80M
Surprise %	-	-	-	-	-	-	-	-	36.30%	41.56%	206.36%	0.20%	0.45%	181.68%	82.23%	0.37%	2.98%	3.73%	2.96%	0.91%	4.73%	7.07%	104.99%	1.13%	0.96%	1.10%

undefined analysts predict VYNE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than VYNE Therapeutics's previous annual EBITDA (undefined) of $NaN.

VYNE Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	13	14	6	6	8	6	7	11	7	13	10	16	8	11	17	14
Net Income	-	-	-	-	-	-	-	-	$-6.19M	$-6.58M	$-10.06M	$-5.62M	$-7.76M	$-9.46M	$-8.48M	$4.67M	$-11.57M	$-21.29M	$-19.92M	$-20.55M	$-23.18M	$-24.71M	$-167.44M	$-40.23M	$-18.87M	$-12.66M
Avg Forecast	$-13.20M	$-12.78M	$-12.78M	$-12.35M	$-12.92M	$-10.01M	$-8.09M	$-39.70M	$-21.29M	$-32.37M	$-109.87M	$-31.39M	$-16.33M	$-120.09M	$-132.23M	$-24.81M	$-190.10M	$-235.07M	$-267.20M	$-22.55M	$-406.27M	$-503.73M	$-741.00M	$-35.45M	$-18.87M	$-11.51M
High Forecast	$-10.34M	$-10.01M	$-10.01M	$-9.67M	$-12.50M	$-7.84M	$-6.34M	$-31.76M	$-16.68M	$-25.35M	$-86.07M	$-25.11M	$-13.06M	$-120.09M	$-132.23M	$-19.85M	$-190.10M	$-235.07M	$-267.20M	$-18.04M	$-406.27M	$-503.73M	$-741.00M	$-28.36M	$-15.10M	$-9.21M
Low Forecast	$-16.06M	$-15.54M	$-15.54M	$-15.03M	$-13.33M	$-12.18M	$-9.84M	$-47.64M	$-25.91M	$-39.38M	$-133.68M	$-37.66M	$-19.60M	$-120.09M	$-132.23M	$-29.77M	$-190.10M	$-235.07M	$-267.20M	$-27.07M	$-406.27M	$-503.73M	$-741.00M	$-42.54M	$-22.65M	$-13.81M
Surprise %	-	-	-	-	-	-	-	-	0.29%	0.20%	0.09%	0.18%	0.48%	0.08%	0.06%	-0.19%	0.06%	0.09%	0.07%	0.91%	0.06%	0.05%	0.23%	1.13%	1.00%	1.10%

VYNE Therapeutics's average Quarter net income forecast for Jun 22 is $-132.23M, with a range of $-132.23M to $-132.23M. VYNE's average Quarter net income forecast represents a -2931.47% decrease compared to the company's last Quarter net income of $4.67M (Mar 22).

VYNE Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	13	14	6	6	8	6	7	11	7	13	10	16	8	11	17	14
SG&A	-	-	-	-	-	-	-	-	$3.88M	$3.03M	$3.22M	$3.24M	$3.71M	$3.95M	$4.30M	$4.42M	$8.20M	$13.83M	$15.84M	$16.62M	$17.90M	$19.77M	$26.46M	$25.41M	$3.75M	$2.70M
Avg Forecast	$2.49M	$2.49M	$2.49M	$2.49M	$3.49M	$2.74M	$2.74M	$2.49M	$3.74M	$3.74M	$1.25M	$156.77M	$1.50M	$1.25M	$2.49M	$9.14M	$100.18M	$118.66M	$158.27M	$118.78M	$117.30M	$82.55M	$39.52M	$39.09M	$3.75M	$2.45M
High Forecast	$2.91M	$2.91M	$2.91M	$2.91M	$4.07M	$3.20M	$3.20M	$2.91M	$4.36M	$4.36M	$1.45M	$188.13M	$1.74M	$1.25M	$2.49M	$9.14M	$100.18M	$118.66M	$158.27M	$118.78M	$117.30M	$82.55M	$39.52M	$39.09M	$4.50M	$2.94M
Low Forecast	$2.08M	$2.08M	$2.08M	$2.08M	$2.91M	$2.28M	$2.28M	$2.08M	$3.12M	$3.12M	$1.04M	$125.42M	$1.25M	$1.25M	$2.49M	$9.14M	$100.18M	$118.66M	$158.27M	$118.78M	$117.30M	$82.55M	$39.52M	$39.09M	$3.00M	$1.96M
Surprise %	-	-	-	-	-	-	-	-	1.04%	0.81%	2.58%	0.02%	2.48%	3.17%	1.73%	0.48%	0.08%	0.12%	0.10%	0.14%	0.15%	0.24%	0.67%	0.65%	1.00%	1.10%

VYNE Therapeutics's average Quarter SG&A projection for Mar 24 is $2.49M, based on 1 Wall Street analysts, with a range of $2.08M to $2.91M. The forecast indicates a -35.85% fall compared to VYNE last annual SG&A of $3.88M (Dec 23).

VYNE Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Mar 19	Mar 18
# Analysts	1	1	1	1	1	1	1	1	1	1	13	14	6	6	8	6	7	11	7	13	10	16	8	11	17	14
EPS	-	-	-	-	-	-	-	-	$-0.60	$-2.01	$-3.07	$-1.73	$-2.60	$-2.94	$-2.63	$1.44	$-3.89	$-7.36	$-6.98	$-7.57	$-8.54	$-10.61	$-86.95	$-68.14	$-58.35	$-51.83
Avg Forecast	$-0.31	$-0.30	$-0.30	$-0.29	$-0.30	$-0.23	$-0.19	$-0.24	$-0.50	$-0.76	$-2.58	$-25.73	$-3.24	$-2.82	$-3.10	$-2.88	$-4.46	$-5.52	$-6.27	$-7.92	$-9.54	$-11.83	$-17.40	$-37.98	$-58.18	$-0.60
High Forecast	$-0.24	$-0.23	$-0.23	$-0.23	$-0.29	$-0.18	$-0.15	$-0.19	$-0.39	$-0.60	$-2.02	$-20.16	$-2.54	$-2.82	$-3.10	$-2.88	$-4.46	$-5.52	$-6.27	$-7.92	$-9.54	$-11.83	$-17.40	$-37.98	$-58.18	$-0.48
Low Forecast	$-0.38	$-0.36	$-0.36	$-0.35	$-0.31	$-0.29	$-0.23	$-0.29	$-0.61	$-0.92	$-3.14	$-31.30	$-3.94	$-2.82	$-3.10	$-2.88	$-4.46	$-5.52	$-6.27	$-7.92	$-9.54	$-11.83	$-17.40	$-37.98	$-58.18	$-0.72
Surprise %	-	-	-	-	-	-	-	-	1.20%	2.64%	1.19%	0.07%	0.80%	1.04%	0.85%	-0.50%	0.87%	1.33%	1.11%	0.96%	0.90%	0.90%	5.00%	1.79%	1.00%	86.38%

According to 8 Wall Street analysts, VYNE Therapeutics's projected average Quarter EPS for Jun 22 is $-3.10, with a low estimate of $-3.10 and a high estimate of $-3.10. This represents a -315.63% decrease compared to VYNE previous annual EPS of $1.44 (Mar 22).

VYNE Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AKTX	Akari Therapeutics	$1.00	$30.00	2900.00%
LGVN	Longeveron	$1.78	$10.00	461.80%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
VYNE	VYNE Therapeutics	$2.64	$5.75	117.80%	Buy
GOVX	GeoVax Labs	$2.27	$4.00	76.21%	Buy
SABS	SAB Biotherapeutics	$4.03	$5.67	40.69%	Buy
KRON	Kronos Bio	$0.96	$1.00	4.17%	Buy
VCYT	Veracyte	$42.24	$35.00	-17.14%	Buy
CDTX	Cidara Therapeutics	$22.81	$12.00	-47.39%	Buy

VYNE Forecast FAQ

Is VYNE Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, VYNE Therapeutics (VYNE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of VYNE's total ratings.

What is VYNE's price target?

VYNE Therapeutics (VYNE) average price target is $5.75 with a range of $5.75 to $5.75, implying a 130.00% from its last price of $2.5. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will VYNE Therapeutics stock go up soon?

According to Wall Street analysts' prediction for VYNE stock, the company can go up by 130.00% (from the last price of $2.5 to the average price target of $5.75), up by 130.00% based on the highest stock price target, and up by 130.00% based on the lowest stock price target.

Can VYNE Therapeutics stock reach $4?

VYNE's average twelve months analyst stock price target of $5.75 supports the claim that VYNE Therapeutics can reach $4 in the near future.

What are VYNE Therapeutics's analysts' financial forecasts?

VYNE Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $460K (high $536.66K, low $383.33K), average EBITDA is $-37.958M (high $-30.379M, low $-45.538M), average net income is $-70.72M (high $-58.441M, low $-82.998M), average SG&A $11.46M (high $13.37M, low $9.55M), and average EPS is $-0.968 (high $-0.814, low $-1.122). VYNE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $400K (high $466.66K, low $333.33K), average EBITDA is $-400K (high $-333K, low $-467K), average net income is $-51.104M (high $-40.032M, low $-62.177M), average SG&A $9.97M (high $11.63M, low $8.31M), and average EPS is $-1.2 (high $-0.94, low $-1.46).

Did the VYNE's actual financial results beat the analysts' financial forecasts?

Based on VYNE Therapeutics's last annual report (Dec 2023), the company's revenue was $424K, which missed the average analysts forecast of $6.64M by -93.62%. Apple's EBITDA was $-27.872M, missing the average prediction of $-30.072M by -7.32%. The company's net income was $-28.452M, missing the average estimation of $-195M by -85.40%. Apple's SG&A was $13.38M, missing the average forecast of $165.49M by -91.92%. Lastly, the company's EPS was $-2.77, missing the average prediction of $-29.57 by -90.63%. In terms of the last quarterly report (Dec 2023), VYNE Therapeutics's revenue was $76K, missing the average analysts' forecast of $150K by -49.33%. The company's EBITDA was $-5.445M, beating the average prediction of $-150K by 3530.00%. VYNE Therapeutics's net income was $-6.188M, missing the average estimation of $-21.294M by -70.94%. The company's SG&A was $3.88M, beating the average forecast of $3.74M by 3.93%. Lastly, the company's EPS was $-0.6, beating the average prediction of $-0.5 by 20.00%